Day 3 - Wednesday, May 20 2026Wednesday, 20 May 2026 - ET (Eastern Time, GMT-05:00)

• Perspective on the OIG's oversight role amidst evolving drug pricing and contracting practices

This session delves into the intricacies of Most Favored Nation (MFN) agreements and the unconventional dynamics shaping negotiations between the U.S. Department of Health and Human Services (HHS) and manufacturers.

Hear from an expert panel of attorneys as they each moderate a topic and interactive discussion among attendees, and themselves, on the most pressing issues facing government and commercial contracting, pricing and reporting.

• Explore market access strategies as CAR-T therapies expand into autoimmune conditions like lupus, addressing the unique challenges of transitioning from academic centers to rheumatology practices and community settings
• Build compelling value propositions using long-term outcome data, hospitalization avoidance metrics, and lifetime treatment cost comparisons that demonstrate CGT's curative potential versus chronic disease management
• Tackle the margin pressures hospitals face with CGT administration, including multi-dose reimbursement complexities, 340B pricing disputes, and the administrative burden of center certification and authorization processes
• Explore innovative contracting models beyond traditional outcomes-based agreements
• Create collaborative frameworks that address price protection requests, streamline prior authorization processes, and support centers in navigating the complex reimbursement landscape while maintaining sustainable business models

Few areas are changing as rapidly as the 340B program. Manufacturers now stand at the intersection—managing a balancing act and fewer options around the best way to manage 340B growth and abuse. The rebate model appears to remain limited, contract pharmacies policy impact and landscape are changing, and 340B claim collection methods are under scrutiny by covered entities.

During this session we will highlight the most critical developments and considerations in each of these areas as well as how more modernized and transparent approaches to 340B that could be considered all while helping establish long-term stability and predictability associated with the 340B program.

• Reflections on shaping rebate strategies within a leading organization
• Broad challenges and considerations in rolling out rebate models
• Background and current regulatory status of 340B

• Explore the latest 2025-2026 trends in brown/white bagging adoption and how payer pressures are reshaping site of care economics across therapeutic areas
• Learn from real-world case studies on successfully transitioning high-cost therapies while maintaining patient outcomes and operational efficiency
• Discover proven manufacturer-health system collaboration frameworks that drive mutual success in site of care optimization initiatives
• Identify the top implementation challenges and tactical solutions for cold chain management, inventory optimization, and patient experience preservation
• Prepare for next-generation site of care models with actionable insights on emerging technologies and evolving payer requirements